EUCTR2015-002801-12-FR进行中（未招募）1 期
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by fluorescence in situ hybridization (FISH) and/or 3+ staining by immunohistochemistry (IHC)
- •Have received previous treatment with a taxane, trastuzumab, pertuzumab, and T-DM1
- •Have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy
- •Have measurable or non-measureable disease assessable by RECIST 1.1
- •At least 18 years of age at time of consent
- •Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
- •Have adequate hepatic function
- •Have adequate baseline hematological parameters
- •Have creatinine clearance = 50 mL/min
- •Have left ventricular ejection fraction (LVEF) = 50%
- •If female of childbearing potential, must have a negative result of serum pregnancy test.
- •Women of childbearing potential and men with partners of childbearing potential must agree to use a highly effective birth control methods.
- •CNS Inclusion
- •Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:
- •- No evidence of brain metastases
- •- Untreated brain metastases not needing immediate local therapy.
- •- Previously treated brain metastases
- •a. Brain metastases previously treated with local therapy my either be stable since treatment or may have progressed since prior local CNS therapy.
- •b. Patients treated with CNS local therapy for newly identified lesions found on initial MRI performed during screening for this study may be eligible to enrol if all of the following criteria are met:
- •i. Time since whole brain radiation therapy (WBRT) is > 21 days prior to first dose of treatment, time since stereotactic radiosurgery (SRS) is > 7 days prior to first dose of treatment, or time since surgical resection is > 28 days
- •ii. Other sites of evaluable disease are present
- •c. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 451
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 29
排除标准
- •Have previously been treated with:
- •a. lapatinib within 12 months of starting study treatment or
- •b. neratinib, afatinib, or other investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously.
- •Have previously been treated with capecitabine for metastatic disease. Note patients who have received capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to starting study treatment are eligible.
- •Have any toxicity related to prior cancer therapies that has not resolved to = Grade 1.
- •Have clinically significant cardiac disease
- •Are known carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease
- •Are known to be positive for human immunodeficiency virus (HIV)
- •Require therapy with warfarin or other coumarin derviatives
- •Unable for any reason to undergo MRI of the brain
- •CNS Exclusion – Based on screening brain MRI, patients must not have any of the following:
- •Any untreated brain metastases > 2.0 cm in size unless discussed with medical monitor and approval for enrolment is given
- •Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total dose of > 2mg dexamethasone.
- •Any lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening MRI may still be eligible for the study based on criteria described under CNS inclusion criteria 20b
- •Known or concurrent leptomeningeal disease (LMD)
研究者
相似试验
进行中（未招募）
1 期
A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamabPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CarcinomaMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002801-12-ATSeagen Inc.600
进行中（未招募）
1 期
A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamabPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CarcinomaMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002801-12-GBSeagen Inc.600
进行中（未招募）
1 期
A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamabEUCTR2015-002801-12-DESeagen Inc.612
进行中（未招募）
1 期
A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamabPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CarcinomaMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002801-12-CZSeattle Genetics, Inc.600
进行中（未招募）
1 期
A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamabPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CarcinomaMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002801-12-ITCASCADIAN THERAPEUTICS INC480